Immune Therapeutics, Inc. Appoints Kevin Phelps as Director
January 08, 2019 at 06:48 pm
Share
On January 2, 2019, the directors of Immune Therapeutics, Inc. appointed Kevin Phelps as a director to fill a vacancy on the Company’s Board of Directors. Mr. Phelps is not appointed to a specific committee and there is currently no arrangement or agreement between Mr. Phelps and the Company. There is no family relationship between Mr. Phelps and any of the Company’s other directors or officers. Mr. Phelps is a finance and business development professional who has spent his career determining, satisfying and managing the operational needs of a wide range of companies. He is a Certified Public Accountant and holds a BS from the University of Notre Dame. With more than 25 years of broad, professional experience, Mr. Phelps has been in senior management positions raising capital for startup companies, managing financial organizations, and developing new businesses through technology, strategic alliances, and acquisition projects for the past 10 years.
Biostax Corp. is a developer and marketer of pharmaceutical, biotechnology, and MedTech products. The Company has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.